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Abstract
Background: The opioid remifentanil induces a decrease of vestibulo-ocular reflex function, which has been
associated with nausea and vomiting when the subjects are moved. The study investigates in healthy female
volunteers if immobility after remifentanil administration protects from nausea and vomiting.
Methods: In volunteers, a standardized movement intervention (a manually applied head-trunk movement forward,
backward and sideward) was started 5 min (session A), 35 min (session B) or 60 min (session C) after cessation of a
remifentanil infusion (0.15 μg · kg−1 · min−1). In a cross-over design, 16 participants were randomized to the early
(sessions A and B) or the late intervention group (sessions A and C). Nausea was assessed using a 11-point
numerical rating scale before and after each movement intervention. Differences within and between groups were
assessed with non-parametric tests for paired and unpaired data.
Results: Comparing sessions A, B and C, intensity of nausea was time-dependent after cessation of remifentanil
administration (p = 0.015). In the early intervention group, nausea decreased from median 5.0 [IQR 1.5;6.0] in session
A to 2.0 [1.0;3.0] in session B (p = 0.094); in the late intervention group nausea decreased from 3.5 [2.0;5.0] in session
A to 0.5 [0.0;2.0] in session C (p = 0.031).
Conclusions: In summary, in young healthy women, immobility after remifentanil administration protects from
nausea and vomiting in a time-dependent manner. In analogy to motion sickness, opioid-induced nausea and
vomiting in female volunteers can be triggered by movement.
Trial registration: German Clinical Trials Register DRKS00010667. The trial was registered retrospectively on June,
20th 2016.
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Background
Opioids are a very important component of the treat-
ment of various pain conditions including moderate and
severe pain, malignant and non-malignant pain as well
as chronic and acute pain [1, 2]. Opioids are the third
among the top therapeutic classes by prescriptions [3]
and are used during general anaesthesia, which is per-
formed several hundred million times a year in the
world [4]. The major reason for reduced patient
compliance and discontinuation of opioid analgesic
treatment are gastrointestinal side effects (i.e., nausea,
vomiting and constipation) along with side affects
regarding the central nervous system [5]. The range of
incidence of nausea and vomiting in patients treated
with opioids for chronic pain is reported between 10 and
50 % [6–9]. Accordingly, opioids have been identified as
an independent risk factor for the development of
postoperative nausea and vomiting (PONV) [10]. The
incidence of PONV is approximately 20–30 % in the
general population [11] which increases up to 80 % in
high-risk patients [10].
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Different pathways of the emetogenic effects of opioids
are still under debate. Predominantly, a direct influence
of opioids in the chemoreceptor trigger zone (CTZ) in
the area postrema by stimulating specific opioid recep-
tors has been discussed [11]. From there, efferent fibers
reach the vomiting center, along with input from three
other major areas, namely: the gastrointestinal tract, the
cerebral cortex and the vestibular apparatus [12]. The
vestibular system has been identified to contribute to
PONV and this is also reflected by the simplified risk
score for predicting PONV after general anaesthesia
[10]. Recently, we showed that the opioid remifentanil
induces a decrease of vestibulo-ocular reflex (VOR)
function [13]. The calculated half-life time of the re-
covery of the VOR function after cessation of the remi-
fentanil administration was 5.3 min [13]. During opioid
administration, movement has been found to trigger
nausea, while immobility protected from nausea. There-
fore we suggested that the intersensory mismatch caused
by the impaired VOR promotes nausea and vomiting.
To provide further evidence that PONV is, at least in
part, based on this pathophysiologic principle, we
hypothesized that the incidence and severity of nausea
depends on the time interval between the stop of remi-




After approval by the Ethics Committee (2411/09,
September 26th, 2011) of the Faculty of Medicine of the
Technische Universität München, the study was con-
ducted with sixteen healthy young women in a random-
ized cross-over design. This design was chosen to rule
out familiarization effects in the participants (mean age
25.8 ± 2.3 years). With the aim of building a sample at
high risk for PONV, only women were invited to partici-
pate. According to the declaration of Helsinki [14], all
subjects provided written informed consent and were
free to withdraw from the experiment at any time of the
investigation.
During each trial, subjects were laying on a stretcher
in a supine position with the upper part of the body ele-
vated at 45°. A patient monitor was used for the surveil-
lance of the vital signs including electrocardiogram,
non-invasive assessment of blood pressure in 5-min in-
tervals and pulse oximetry. The head was stabilized with
a tape in order to avoid any movement of the head. After
placement of an intravenous line in an antecubital vein,
continuous administration of the opioid remifentanil
was started using a syringe pump (B. Braun, Melsungen,
Deutschland) with a rate of 0.15 μg · kg−1 · min−1. Remi-
fentanil was chosen due to its well-known pharmacoki-
netic characteristics and a steady-state plasma level after
a short time of continuous intravenous administration
(90 % after 17 min). The context-sensitive half-life time
is 3.7 min after stopping the drip [15]. After 30 min, the
administration of remifentanil was stopped.
The participants were randomized into two groups
(early intervention vs. late intervention). Three different
sessions (A, B, C), combined in a cross-over design, were
conducted. There was at least a one-day wash-out period
between the measurements (Fig. 1).
In session A, the tape stabilizing the head was
removed 5 min after stopping the administration of
remifentanil and every subject’s head-trunk was bent
manually in ± 45° forward, backward and sideward
twenty times with a frequency of 1 Hz. In session B, the
participants were moved identically but the intervention
was started 35 min after stopping the administration of
remifentanil. In session C, the same movement interven-
tion took place 60 min after stopping the administration
of remifentanil. The time periods of 35 min and 60 min
were chosen because of the pharmacokinetic properties
of remifentanil. The plasma concentrations are decreas-
ing over the time and the concentration at 60 min is not
be predicted to have clinically relevant effects [15]. The
sessions differed only in the time interval (5 vs. 35 and 5
vs. 60 min) between stopping the administration of
remifentanil and the movement intervention. In all ses-
sions, subjects laid in a semirecumbent position, the
head-stabilizing tape was removed immediately prior to
the movement intervention.
Assessment of nausea
Maximum nausea scores (experienced at the relevant
time period) were noted in arbitrary values on a numer-
ical rating scale (NRS) ranging from 0 (“everything
okay”) to 10 (“vomiting”). The 11-point scale was chosen
in analogy to Apfel et al. [16] and our previous work
[13]. The participants rated their maximum nausea just
before remifentanil initiation (NRS0), for the period of
30 min during opioid administration (NRSRemi) until just
before movement, and for the period of 60 min after one
of the movement interventions (NRSpost for sessions A,
B, C).
Subjects
The subjects did not suffer from balance disorders,
headache or any other neurological diseases. They were
not taking any medication, explicitly no opioids. Because
of its ubiquitous use in anesthesiology to predict the risk
for PONV [10], we used the Apfel-Score and included
only volunteers which were classified to be part of a high
risk population. Subjects were requested to fast for 6 h
and to abstain from alcohol and smoking for more than
24 h before the tests. They received financial compensa-
tion for participating in the study.
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Statistical analysis
To further provide evidence that moving the subjects
triggers nausea we compared nausea before the move-
ment trigger (NRS0, NRSRemi) with nausea for those
trials where the subjects were moved immediately after
stopping remifentanil administration (NRSpost). To test
the hypothesis that the immobility after remifentanil
administration protects from developing nausea and
vomiting, we compared nausea of the trials with imme-
diate movement (NRSpost, session A) with those trials
where subjects were moved after 35 and 60 min after
stopping remifentanil administration (session B, C). The
distribution of continuous data is presented by median
and interquartile range (IQR). Corresponding hypothesis
testing across study groups was performed by Mann-
Whitney-U and Kruskal-Wallis tests. Paired samples
within study groups were compared by means of
Wilcoxon signed rank tests. All statistical testing was
performed on two-sided exploratory 5 % significance
levels. Computations were conducted with SPSS (SPSS
Statistics for Windows, Version 22.0. Armonk, NY) and
R system for statistical computing [17].
Results
The 16 participants were randomized to the groups
(Fig. 1). One subject terminated the participation before
session A was completed. The two groups were compar-
able referring to age. According to the inclusion criteria,
each subject had a PONV risk of 61 % [10]. No subject
indicated nausea before any trial (n = 30, NRS0 = 0
throughout). During 30 min of remifentanil administra-
tion (NRSRemi), a small increase was detected (n = 30,
Median [IQR] NRSRemi = 0.5 [0.0;1.3]).
Nausea after movement intervention
When subjects were moved 5 min after stopping
remifentanil administration (Session A, n = 15), they
indicated significantly more nausea (Median [IQR]
NRSpost = 4.0 [2.0;6.0]) than before movement (Median
[IQR] NRSRemi = 0.0 [0.0;2.0], p < 0.001). When compar-
ing Session A, B and C, which are characterized by an
increasing time interval between the stop of remifentanil
administration and the movement intervention, the sub-
jects indicated less nausea (p = 0.015, Fig. 2).
Fig. 1 Study design
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When subjects were moved 35 or 60 min (Session B
or C, respectively) after stopping the remifentanil drip,
they indicated less nausea compared to their own con-
trol at the immediate intervention in session A. In the
early intervention group, nausea decreased from 5.0
[1.5;6.0] in session A to 2.0 [1.0;3.0] in session B; in the
late intervention group the nausea decreased from 3.5
[2.0;5.0] in session A to 0.5 [0.0;2.0] in session C (Fig. 3).
Discussion
The present study indicates that there may be a time
interval after the administration of the opioid remifenta-
nil, during which head immobility protects from nausea.
The more time the participants’ head rested immobile
between administration of remifentanil and the move-
ment intervention the less nausea was indicated (Fig. 2).
This is probably due to the recovery of the VOR gain
from remifentanil-induced depression, which has been
shown to reflect the pharmacokinetics of the drug [13].
In our previous work we suggested that this decrease in
VOR evokes a perceptual mismatch of multisensory input
when the head is moved, which results in nausea [13].
This pathophysiologic principle is further supported by
the present study. As in our previous work, moving pa-
tients triggered nausea during remifentanil administration.
Consistently, we found a continuous decrease of nau-
sea between the session A and B or C, respectively, in
the intra-group analysis. Some results did not provide
statistical significance, specifically, the difference in the
early intervention group between the sessions A and B
(p = 0.094), and the inter-group comparison between the
sessions B and C (p = 0.067). As the trends were in line
to what was expected according to the investigated
pathophysiological principle, we suggest that this is due
to the small sample size.
As in our prior study, even before any movement,
participants indicated slightly more nausea (Median
NRSRemi = 0.5) than before initiating the administration
of remifentanil (NRS0 = 0). We suggest that this increase
is of minor clinical importance and might be attributable
to combined effects on the CTZ and the vestibular
system [11, 13]. Generally, the nausea indicated was
relatively high compared to what the PONV score pre-
dicted. This is not surprising in light of the movement
Fig. 2 Differences in participants’ perceived nausea between the sessions A, B and C. Box plots represent medians, quartiles and range. Nausea
and vomiting given as values on a numerical rating scale ranging form 0 to 10
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intervention, which possibly overestimates the motion-
induced mechanism, because the movement stimuli
were of high intensity.
Our findings raise further questions with respect to
the underlying pathophysiologic principles. First, do
other μ-agonists similarly impact the VOR or do differ-
ent opioids modulate the vestibular system differently,
which could explain less nausea after opioid rotation in
some patients? [18–20] Currently, there are different
explanations for an improved tolerance of an opioid
therapy after rotation, e.g. reduction of the opioid dosing
[18], or changes in the receptor-effector relationships
during a prolonged morphine exposure [21]. Second, it
is of interest whether patients suffering from chronic
pain treated with opioids adapt to a compromised VOR
or whether the VOR itself recovers over time even under
opioid treatment. In chronic pain patients, the number
of patients indicating nausea after beginning a treatment
with opioids, ranges from 10 to 50 % [6–9]. After a few
days, an antiemetic therapy can be withdrawn as a con-
sequence of tolerance to this side effect [22]. These pa-
tients are able to adapt (as opposed to constipation
which normally requires on-going treatment). This may
be similar to motion sickness where habituation is con-
sidered to be an important mechanism of adaption in
case of continuous intersensory mismatch [23, 24]. This
habituation is slowed by scopolamine, which has been
suggested to inhibit the normal activation of the central
Fig. 3 Differences in participants’ perceived nausea between the sessions A, B and C. Box plots represent medians, quartiles and range. Nausea
and vomiting given as values on a numerical rating scale ranging form 0 to 10
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nervous system and thus, to prompt compensatory reac-
tions [24]. This leads to the third question that is
whether some antiemetics including scopolamine, a drug
for prevention of motion sickness, has its beneficial ef-
fects for the treatment of PONV through its effects on
the vestibular system [25, 26].
Given the analogies between the pathophysiologic
principle investigated here and the mismatch theory of
motion sickness, it is not surprising that there is an
increased incidence of PONV after certain types of
surgery including strabismus surgery, which itself can
cause a intersensory mismatch [10, 27]. A history of
motion sickness itself has been identified as an inde-
pendent predictor of PONV as represented in Apfel’s
risk score for PONV [10]. Therefore, the findings of our
study might be of clinical relevance in settings where
general anaesthesia including remifentanil is adminis-
tered and where post-operative pain is quite low and
controlled well with non-opioid analgesics. Furthermore,
the results of the present study may explain why patients
in the increasing sector of outpatient surgery with im-
mediate or very early mobilization suffer from PONV
more frequently than patients in inpatient settings [28].
This study was not designed to identify a specific time
interval during which immobility protects patients from
PONV. It remains to investigate this hypothesized time
interval in the future. Furthermore, such a time interval
of vulnerability to PONV should be adapted to the indi-
vidual susceptibility for PONV. Consequently, it would
justify a recommendation not to move the patients after
specific procedures.
Some limitations have to be considered. The sample
size in this exploratory approach was relatively small
and only women were tested in order to investigate a
sample with high risk for PONV. Future studies will re-
veal whether also men would benefit from a immobility
period after administration of remifentanil.
Conclusions
This study in volunteers receiving only remifentanil
showed that a time interval of immobility after remifen-
tanil administration might protect from nausea and
vomiting in a population at high risk for PONV. The
results provide further evidence that the origin of PONV
is multifactorial including opioid effects on the CTZ and
the vestibular system. For the recommendation of a
specific time interval for e.g. outpatient settings, larger
studies in clinical settings are required.
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